Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
BioCryst Pharmaceuticals, Inc. (BCRX) had Receiveable Turnover of 5.82 for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$331.41M |
|
$-226.54M |
|
$4.48M |
|
$326.93M |
|
$435.12M |
|
$-103.71M |
|
$-122.52M |
|
$-226.23M |
|
$-226.23M |
|
$-226.54M |
|
$-226.54M |
|
$-226.54M |
|
$-226.54M |
|
$-103.71M |
|
$-112.32M |
|
192.20M |
|
192.20M |
|
$-1.18 |
|
$-1.18 |
|
| Balance Sheet Financials | |
$495.97M |
|
$7.91M |
|
$20.99M |
|
$516.96M |
|
$149.99M |
|
$814.11M |
|
$822.50M |
|
$972.49M |
|
$-455.53M |
|
$-455.53M |
|
$-455.53M |
|
205.77M |
|
| Cash Flow Statement Financials | |
$-95.14M |
|
$-131.50M |
|
$32.48M |
|
$306.24M |
|
$112.45M |
|
$-193.79M |
|
$55.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.31 |
|
-- |
|
-- |
|
2.27 |
|
-1.84 |
|
98.65% |
|
-31.29% |
|
-31.29% |
|
-33.89% |
|
-68.26% |
|
-68.36% |
|
$-97.31M |
|
-- |
|
-- |
|
-- |
|
0.64 |
|
0.16 |
|
|
Receiveable Turnover |
5.82 |
62.72 |
|
49.73% |
|
49.73% |
|
-43.82% |
|
-63.18% |
|
$-2.21 |
|
$-0.51 |
|
$-0.49 |
|